IGC Pharma, Inc.

Equities

IGC

US45408X3089

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
0.458 ^USD	+6.51%		-6.53%	+63.51%

Apr. 16	IGC Pharma, Inc Announces Interim Data from Its Phase 2 Clinical Trial Demonstrates Clinically Significant Reduction, Approaching Statistical Significance, in Agitation in Alzheimer?S At Week Two Compared to Placebo	CI
Mar. 22	Aurora, Canopy Among Cannabis Stocks Rising After Germany Passes Partial Legalization Law	MT

IGC Pharma, Inc. Reports Earnings Results for the Full Year Ended March 31, 2023

July 07, 2023 at 04:16 pm EDT

IGC Pharma, Inc. reported earnings results for the full year ended March 31, 2023. For the full year, the company reported sales was USD 0.911 million compared to USD 0.397 million a year ago. Net loss was USD 11.51 million compared to USD 15.02 million a year ago.

Basic loss per share from continuing operations was USD 0.22 compared to USD 0.3 a year ago.

Latest news about IGC Pharma, Inc.

IGC Pharma, Inc Announces Interim Data from Its Phase 2 Clinical Trial Demonstrates Clinically Significant Reduction, Approaching Statistical Significance, in Agitation in Alzheimer?S At Week Two Compared to Placebo	Apr. 16	CI
Aurora, Canopy Among Cannabis Stocks Rising After Germany Passes Partial Legalization Law	Mar. 22	MT
Aurora Cannabis, Canopy Growth Among Cannabis Stocks Rising After Germany Passes Partial Legalization Law	Mar. 22	MT
IGC Pharma, Inc. announced that it expects to receive $3 million in funding from Bradbury Asset Management (Hong Kong) Limited	Mar. 21	CI
IGC Pharma, Inc Announces the Results of an Interim Analysis of its Ongoing Phase 2 Trial Investigating IGC-Ad1 as Treatment for Agitation in Dementia from Alzheimer?s Disease	Mar. 20	CI
Igc Pharma, Inc. Appoints Terry Lierman as Independent Director to Its Board of Directors	Mar. 12	CI
IGC Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 14	CI
IGC Pharma Announces Tgr-63 Reduces Agitation in Alzheimer's Mouse Model	Feb. 01	CI
IGC Pharma, Inc. Provides Details on its Drug Candidate TGR-63	Jan. 23	CI
Igc Pharma, Inc. Activates Clincloud, One of 12 Sites in Ongoing Phase 2B Alzheimer?S Trial	Jan. 17	CI
Patent Granted to IGC Pharma for Groundbreaking Drug Formulation to Treat Agitation in Alzheimer's	Dec. 19	CI
IGC Pharma, Inc. Announces an Artificial Intelligence Collaboration with Los Andes University?s Center for Research and Training in Artificial Intelligence	Dec. 06	CI
IGC Pharma, Inc. Announces Master Agreement with University of Los Andes to Advance AI Initiatives	Nov. 21	CI
Earnings Flash (IGC) IGC PHARMA Posts Q2 Revenue $291,000	Nov. 13	MT
IGC Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 09	CI
IGC Pharma Receives European Patent for Cannabinoid Pain Treatment	23-10-19	MT
North American Morning Briefing : Treasury Yields Keep Pushing Higher	23-08-17	DJ
Earnings Flash (IGC) IGC PHARMA Reports Q1 Revenue $555,000	23-08-14	MT
IGC Pharma, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-10	CI
IGC Pharma Expands Phase 2 Trial of IGC-Ad1 to Include the University of Puerto Rico	23-08-02	CI
IGC Pharma, Inc. Presents 6 Posters on the Positive Impact of IGC-AD1 on Neuropsychiatric Symptoms in Dementia at the 2023 Alzheimer's Association International Conference	23-07-18	CI
IGC Pharma, Inc. Reports Earnings Results for the Full Year Ended March 31, 2023	23-07-07	CI
IGC Pharma, Inc. Enters into Master Loan and Security Agreement	23-07-07	CI
IGC Pharma to Raise $3 Million in Gross Proceeds From Private Placement	23-07-06	MT
IGC Pharma, Inc. announced that it expects to receive $3 million in funding	23-07-05	CI

Chart IGC Pharma, Inc.

Duration

Period

More charts

Company Profile

IGC Pharma, Inc. is a clinical-stage pharmaceutical company. It develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimerâs disease, period cramps, premenstrual syndrome, and chronic pain. Its segments include Life Sciences and Infrastructure. It has two investigational drug assets targeting Alzheimerâs disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimerâs cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimerâs disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol (THC) based formulation that is in a 146-person phase II clinical trial for agitation in dementia due to Alzheimerâs. TGR-63, a non-cannabinoid molecule, is an enzyme inhibitor shown in pre-clinical trials to reduce neurotoxicity in Alzheimerâs cell lines. It also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.

Sector

Biotechnology & Medical Research

Calendar

2024-06-19 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.458 USD

Average target price

3.25 USD

Spread / Average Target

+609.61%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IGC PHARMA, INC.	+63.51%	30.26M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research